Prescribers letter

Veradigm ePrescribe is an electronic prescribing solution that provides a comprehensive and user-friendly experience for both physicians and patients. It offers various features to ensure that prescribers and patients are covered throughout the prescribing process.With Veradigm ePrescribe, physicians can choose between low-cost e-prescribing that saves time and eliminates the need for paper prescriptions, or advanced e-prescribing that keeps them up to date with regulatory mandates. This versatility allows physicians to customize their experience to suit their needs and preferences.With over 140,000 prescribers using Veradigm ePrescribe for hundreds of millions of transactions annually, it is a trusted and proven choice for electronic prescribing. Additionally, Veradigm ePrescribe’s mobile compatibility provides physicians with the flexibility to prescribe from anywhere they have internet access.Veradigm ePrescribe offers several benefits, including improved medication adherence, satisfaction, and efficiency. It allows physicians to prescribe electronically within their clinical workflow, saving time and streamlining the prescribing process. Overall, Veradigm ePrescribe is a reliable and efficient solution for electronic prescribing that can benefit both physicians and patients.

Your site. And most consumers know how crappy that is — e.g. they already bought the item and then they see tons of ads for the exact same item. Too many marketers are paying extra for hyper targeting — using many targeting parameters, thinking that it makes the ads more relevant for users. Research has shown that it doesn’t. (See: Despite Claims That More Targeting Means More Relevant Ads, Nope. Here’s Proof.) In fact, consumers are seeing far too many ads that are not relevant that they have taken action to protect themselves - by installing ad blockers. Over-Targeting and Campaign EffectivenessAdvertisers have gone too far down the rabbit hole of targeting in digital advertising. They have been misled by ad tech companies because the more targeting parameters they buy, the more revenue the ad tech companies make. Advertisers are over-targeting individuals and under-spending in basic brand building — exposing new potential customers to their brand and product. By doing so they are “leaving large sums of money on the table.” To illustrate with a more specific example — pharmaceutical companies have been desperately trying to target the 1% “high-prescribers” — doctors who already prescribe a lot of their particular drug. These advertisers are neglecting showing ads to the other 99% of doctors who are “low- to no-prescribers.” This much larger group may simply not be aware of the pharma company or their drug. If the pharma advertisers rebalanced their digital ad spending to include more brand-building and less over-targeting, they could drive a lot more sales. Small increases from a group that is 99X larger than the “high-prescribers” group far outweighs eking out a few more prescriptions from doctors who already prescribe a lot. Furthermore, most marketers don't need to know which specific individual bought something from them; they just need to know that more people bought something as a result of being exposed to the ads. This means that 3P cookies, which represent the individual are not necessary in the determination of whether campaigns worked. As long as advertisers can see “exposed” versus “not-exposed” and that exposed users

Cannabis strains are specific types of cannabis plants with certain properties or effects. They are used in a variety of different medical cannabis products to help treat patients with a variety of health conditions. The most common strains available in Australia are Sativa, Indica, or a hybrid of these two strains. Understanding how each strain affects different products is crucial to tailoring a treatment plan for patients. Little Green Pharma (LGP) is an industry-leading medical cannabis manufacturer in Australia. We offer valuable information and resources for prescribers, and pharmacists, who want to learn about the diverse legal medicinal cannabis landscape.What cannabis strains are used for medical cannabis?There are a variety of cannabis strains used for medical cannabis products. Different strains exhibit different tetrahydrocannabinol (THC) to cannabidiol (CBD) ratios that may assist registered medical practitioners when prescribing medicinal cannabis products to address the specific needs of their patients. The different types of strains found in medical cannabis are cultivated to produce specific effects which may benefit patients with a range of medical conditions. Their distinctive qualities allow registered medical practitioners to create personalised treatment plans for patients, along with other medications, to alleviate certain health conditions. When choosing a medicinal cannabis flower strain, there are a few elements that need to be considered by prescribers. Firstly, there is the percentage of THC and CBD in the product. This is important because for many, THC can cause psychoactive effects and is not a suitable treatment option. Someone with THC in their system may not legally drive or operate heavy machinery in most parts of Australia. This does not suit the lifestyle of certain patients. Another important consideration is the terpene profile of the product. Terpenes, especially in combination with one another, can augment the effects of cannabinoids (e.g. THC & CBD). This

Us—we just unplugged from Allscripts to ensure no transfer of data. Our systems remained operational.”In messages to its 2,300 members via social media, the New York American College of Emergency Physicians noted that it received an update from the state’s Department of Health that “a cyber incident regarding AllScripts has occurred” affecting “the ability for hospitals, clinics, nursing homes, individual prescribers and pharmacies to transmit and receive prescription electronically.” Prescribers in the states using Allscripts services for placing drug orders were allowed to use “paper official prescriptions” until services are restored, the group reported. In a published statement, Allscripts acknowledged the attack has affected clients’ services, but offered few specifics.“We are investigating a ransomware incident that has impacted a limited number of our applications,” the Allscripts statement noted. “We are working diligently to restore these systems, and most importantly, to ensure our clients’ data is protected.”Further, Allscripts believes that no data had been accessed or deleted in the ransomware attack.“Although our investigation is ongoing, there is currently no evidence that any data has been removed from our systems,” the company noted. “We regret any inconvenience caused by this temporary outage.”Conference calls over the weekend by the company indicated that service outages were continuing, and that the outage was expected to continue into Monday.Posts from providers on Twitter on Sunday noted that they were not able to access patient information from Allscripts.Yvette Crabtree, MD, an internal medicine physician with Sunflower Medical Group in Mission, Kan., reported in a Twitter post Friday that “the attack on Allscripts has taken down our e-prescribing, EPCS and some other services.”Industry reports of outages notwithstanding, Allscripts clients should be aware the company is being more upfront about the attack than many other vendors are, says Allen Briskin, a senior counsel at the Pillsbury, Winthrop Shaw Pittman

ServicesPromote the use of overdose-reversing drugsUse public health surveillance to better understand the opioid epidemicSupport research on pain and addictionAdvance better practices in pain managementSome interventions that are currently being studied are: Vaccines that target opioids in the blood to stop them from reaching the brain and causing a highStudies are underway to determine the best way to to provide care to those in need of SUD treatment and how to educate providers on choosing the most appropriate treatments for patients with OUD Research on the most effective ways to deliver evidence-based prevention and treatment services to youth before exposure to opioids put them at risk for OUDHow can community pharmacists prevent and treat opioid use disorder?There are several ways the community pharmacist may be able to have an impact: Screening, management, and education on the safe use of prescription opioids As part of their duties in filling and dispensing prescription drugs, pharmacists evaluate the clinical appropriateness of each prescription. Pharmacists are legally required by federal law to ensure that all prescriptions for controlled substances, including opioids, are prescribed for a legitimate medical purpose and that there is a prescriber-patient relationship. Some things the community pharmacist should look out for: Forged or altered prescriptionsFills at multiple pharmaciesEarly refillsCash paymentsMultiple prescribers (aka doctor shopping)Frequent and consistent utilization of prescription drug monitoring programs (PDMP data) can help to identify opioid misuse. Be aware of state specific laws regarding the use of PDMP when filling and dispensing prescriptions for opioids. With every opioid prescription dispensed, pharmacists should provide education to the patient about opioid safety (harm reduction programs) side effects, proper use, and disposal of any remaining medication. Pharmacies can register with the Drug Enforcement Agency (DEA) to become a registered collection site for unused medications to help reduce access to opioids. Naloxone distributionNaloxone is a live-saving antidote to opioid overdose–but it must be available to the public to have an impact. Increasing access to naloxone at community pharmacies without a prescription has been key in increasing naloxone distribution and decreasing opioid overdose deaths. Community pharmacists can offer this life-saving treatment to those interested and provide education on the use of naloxone in opioid overdose. The passage of naloxone access laws that provide legal immunity to prescribers, expand prescribing authority or allow collaborative practice agreements allowing pharmacist prescribing of naloxone, and expanded insurance coverage for naloxone have greatly increased the amount of naloxone dispensed from community pharmacies. Dispensing medications for opioid use disorderCommunity pharmacists play a huge role in the treatment of OUD by having medications for opioid use disorder (MOUD) in stock and providing education to patients when dispensing them. Pharmacists can also establish relationships with providers in the area who treat